Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mirati Therapeutics Inc.
Synthekine
Dragonfly Therapeutics
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Boehringer Ingelheim
Merck Sharp & Dohme LLC
Duke University
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Bristol-Myers Squibb
BioNTech SE
Bristol-Myers Squibb
Seagen Inc.
Genmab
Merck Sharp & Dohme LLC
Seagen Inc.
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Astellas Pharma Inc
AstraZeneca
Merck Sharp & Dohme LLC
Xencor, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Mirati Therapeutics Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Merck Sharp & Dohme LLC
Eli Lilly and Company
Hoffmann-La Roche
iLeukon Therapeutics, Inc.
Merck Sharp & Dohme LLC
Roswell Park Cancer Institute
Emory University
NeoImmuneTech
Arcus Biosciences, Inc.
University of Pittsburgh
Revolution Medicines, Inc.
Verastem, Inc.
Wake Forest University Health Sciences
H. Lee Moffitt Cancer Center and Research Institute
Hoffmann-La Roche
Genmab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Exelixis
Eli Lilly and Company